Upfront Treatment With Chemotherapy and Bevacizumab in Advanced Ovarian Cancer
Status:
Not yet recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
Our study aims at assessment of response, survival and toxicity of frontline treatment with
chemotherapy and Bevacizumab in patients having advanced epithelial ovarian cancer.